RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.
[1][2] Its route of administration was unspecified.
[1] The drug reached phase 1 clinical trials prior to the discontinuation of its development.
[1][2] It was under development by Hoffmann-La Roche.
[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.